<?xml version='1.0' encoding='utf-8'?>
<document id="12831340"><sentence text="A review of the clinical efficacy and tolerability of almotriptan in acute migraine."><entity charOffset="54-65" id="DDI-PubMed.12831340.s1.e0" text="almotriptan" /></sentence><sentence text="Almotriptan is a serotonin (5-hydroxytryptamine, 5HT)(1B/1D)-receptor agonist approved for the acute treatment of migraine"><entity charOffset="0-11" id="DDI-PubMed.12831340.s2.e0" text="Almotriptan" /><entity charOffset="17-26" id="DDI-PubMed.12831340.s2.e1" text="serotonin" /><entity charOffset="28-47" id="DDI-PubMed.12831340.s2.e2" text="5-hydroxytryptamine" /><pair ddi="false" e1="DDI-PubMed.12831340.s2.e0" e2="DDI-PubMed.12831340.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12831340.s2.e0" e2="DDI-PubMed.12831340.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12831340.s2.e0" e2="DDI-PubMed.12831340.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12831340.s2.e1" e2="DDI-PubMed.12831340.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12831340.s2.e1" e2="DDI-PubMed.12831340.s2.e2" /></sentence><sentence text=" In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12"><entity charOffset="113-124" id="DDI-PubMed.12831340.s3.e0" text="almotriptan" /></sentence><sentence text="5 mg was effective and well-tolerated" /><sentence text=" Almotriptan maintains a consistency of response across three attacks and patients continue to respond to almotriptan for up to 1 year"><entity charOffset="1-12" id="DDI-PubMed.12831340.s5.e0" text="Almotriptan" /><entity charOffset="106-117" id="DDI-PubMed.12831340.s5.e1" text="almotriptan" /><pair ddi="false" e1="DDI-PubMed.12831340.s5.e0" e2="DDI-PubMed.12831340.s5.e0" /><pair ddi="false" e1="DDI-PubMed.12831340.s5.e0" e2="DDI-PubMed.12831340.s5.e1" /></sentence><sentence text=" Results from two comparative studies and a meta-analysis of 53 randomised, placebo-controlled studies of oral triptans in &gt; 24,000 patients, confirm that almotriptan 12"><entity charOffset="155-166" id="DDI-PubMed.12831340.s6.e0" text="almotriptan" /></sentence><sentence text="5 mg demonstrates comparable efficacy with sumatriptan 50 and 100 mg"><entity charOffset="43-54" id="DDI-PubMed.12831340.s7.e0" text="sumatriptan" /></sentence><sentence text=" The incidence of treatment-related adverse events with almotriptan is comparable to that of placebo and significantly lower than that with sumatriptan"><entity charOffset="56-67" id="DDI-PubMed.12831340.s8.e0" text="almotriptan" /><entity charOffset="140-151" id="DDI-PubMed.12831340.s8.e1" text="sumatriptan" /><pair ddi="false" e1="DDI-PubMed.12831340.s8.e0" e2="DDI-PubMed.12831340.s8.e0" /><pair ddi="false" e1="DDI-PubMed.12831340.s8.e0" e2="DDI-PubMed.12831340.s8.e1" /></sentence><sentence text=" Drug-drug interaction studies indicate that almotriptan may be coadministered with other commonly prescribed drugs without dose modification"><entity charOffset="45-56" id="DDI-PubMed.12831340.s9.e0" text="almotriptan" /></sentence><sentence text=" Almotriptan can be recommended as first-line treatment for acute migraine"><entity charOffset="1-12" id="DDI-PubMed.12831340.s10.e0" text="Almotriptan" /></sentence><sentence text="" /></document>